H.R. 2821 · 119th Congress (2025–2027)
FDA Modernization Act 3.0
This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug.
The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications.
The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.
Show official title
To require the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to publish a final rule relating to nonclinical testing methods.
Passed House
This bill’s path
466 days after it was introduced
This is H.R. 2821’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced15 months
Passed House
Passed Senate
Sent to President
Signed into law
- Sponsor
- Rep. Earl L. "Buddy" Carter (R-GA-1)
- Cosponsors
41 cosponsors
5 original · 36 later
20 R · 21 D
- Rep. Vern Buchanan (R-FL-16)· Original · Apr 10, 2025
- Rep. Nanette Diaz Barragán (D-CA-44)· Original · Apr 10, 2025
- Rep. Troy A. Carter (D-LA-2)· Original · Apr 10, 2025
- Rep. Rosa L. DeLauro (D-CT-3)· Original · Apr 10, 2025
- Rep. Diana Harshbarger (R-TN-1)· Original · Apr 10, 2025
- Rep. Lloyd Doggett (D-TX-37)· Later · Apr 14, 2025
- Rep. Dan Crenshaw (R-TX-2)· Later · Apr 17, 2025
- Rep. Mike Carey (R-OH-15)· Later · Apr 17, 2025
- Rep. Brian K. Fitzpatrick (R-PA-1)· Later · Apr 17, 2025
- Rep. Nicole Malliotakis (R-NY-11)· Later · Apr 17, 2025
- Rep. Jerrold Nadler (D-NY-12)· Later · Apr 17, 2025
- Rep. Judy Chu (D-CA-28)· Later · Apr 29, 2025
- Rep. Daniel S. Goldman (D-NY-10)· Later · Apr 29, 2025
- Rep. Darren Soto (D-FL-9)· Later · Apr 29, 2025
- Rep. Hillary J. Scholten (D-MI-3)· Later · Apr 29, 2025
- Rep. Jay Obernolte (R-CA-23)· Later · May 13, 2025
- Rep. Josh Gottheimer (D-NJ-5)· Later · May 20, 2025
- Rep. Jason Crow (D-CO-6)· Later · Jun 6, 2025
- Rep. Ted Lieu (D-CA-36)· Later · Jun 27, 2025
- Rep. Christopher H. Smith (R-NJ-4)· Later · Jul 2, 2025
- Rep. Claudia Tenney (R-NY-24)· Later · Jul 2, 2025
- Del. Eleanor Holmes Norton (D-DC)· Later · Jul 10, 2025
- Rep. Maria Elvira Salazar (R-FL-27)· Later · Jul 10, 2025
- Rep. Lois Frankel (D-FL-22)· Later · Jul 14, 2025
- Rep. Josh Harder (D-CA-9)· Later · Jul 14, 2025
- Rep. David G. Valadao (R-CA-22)· Later · Jul 14, 2025
- Rep. Gus M. Bilirakis (R-FL-12)· Later · Jul 16, 2025
- Rep. Scott Fitzgerald (R-WI-5)· Later · Jul 16, 2025
- Rep. Laurel M. Lee (R-FL-15)· Later · Jul 17, 2025
- Rep. Ken Calvert (R-CA-41)· Later · Jul 22, 2025
- Rep. Eugene Simon Vindman (D-VA-7)· Later · Sep 11, 2025
- Rep. Mark Pocan (D-WI-2)· Later · Nov 4, 2025
- Rep. Michael Lawler (R-NY-17)· Later · Nov 20, 2025
- Rep. Randy K. Weber, Sr. (R-TX-14)· Later · Dec 2, 2025
- Rep. Joe Neguse (D-CO-2)· Later · Dec 11, 2025
- Rep. Raja Krishnamoorthi (D-IL-8)· Later · Dec 15, 2025
- Rep. Thomas H. Kean, Jr. (R-NJ-7)· Later · Jan 7, 2026
- Rep. Julie Johnson (D-TX-32)· Later · Jan 15, 2026
- Rep. Young Kim (R-CA-40)· Later · Apr 22, 2026
- Rep. Nicholas A. Langworthy (R-NY-23)· Later · May 12, 2026
- Rep. Shri Thanedar (D-MI-13)· Later · Jun 2, 2026
- Policy area
- Health
- Subjects
- Administrative law and regulatory procedures
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Medical research
- Research administration and funding
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
▸ 7 committee actions · Apr 10, 2025 – Jun 18, 2026
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Subcommittee markup session held
Subcommittee Consideration and Mark-up Session Held
Sources
- Congress.gov action
- House committee actions
Forwarded by subcommittee
Forwarded by Subcommittee to Full Committee by Voice Vote.
Sources
- Congress.gov action
- House committee actions
Markup session held
Committee Consideration and Mark-up Session Held
Sources
- Congress.gov action
- House committee actions
Ordered reported
Ordered to be Reported by the Yeas and Nays: 44 - 0.
Sources
- Congress.gov action
- House committee actions
Reported by committee
Reported by the Committee on Energy and Commerce. H. Rept. 119-706.
Sources
- Congress.gov action
- House floor actions
- Latest
Passed House
On motion to suspend the rules and pass the bill Agreed to by voice vote.
The House passed the bill.
Document: Engrossed in House
Sources
- Congress.gov action
- House floor actions
Committees
- HouseEnergy and CommerceReferred Apr 10, 2025 · Markup May 21, 2026 · Reported Jun 18, 2026H. Rept. 119-706
May 13, 2026 · Markup
Jul 16, 2025 · Hearing
Jul 9, 2025 · Hearing
Floor record
i
Explicit consideration evidence: the measure’s bill-status citation matched a GovInfo title, headline, or first paragraph. Incidental mentions are not listed.
Jul 20, 2026 · House · Considered under suspension of the rulesCongressional Record H4639–H4640
Fda Modernization Act 3.0
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
Titles (2)
FDA Modernization Act 3.0
Display title, Short title · Engrossed in House, Reported in House, Introduced in House
To require the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to publish a final rule relating to nonclinical testing methods.
Official title · Engrossed in House, Introduced in House